Incorporation of ortho- and meta-tyrosine into cellular proteins leads to erythropoietin-resistance in an erythroid cell line

Kidney and Blood Pressure Research

Volumn 38, Issue 2-3, 2013, Pages 217-225

  Mikolás, Esztella ^a   Kun, Szilárd ^a   Laczy, Boglárka ^a   Molnár, Gergo A ^a   Sélley, Eszter ^a   Koszegi, Tamás ^b   Wittmann, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Cell signaling; Erythropoietin resistance; Oxidative stress; Tyrosine isomers

Indexed keywords

3 (2 HYDROXYPHENYL)ALANINE; CELL PROTEIN; ERYTHROPOIETIN; HYDROXYL RADICAL; META TYROSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLALANINE; STAT5 PROTEIN; TYROSINE; PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ARTICLE; CELL COUNTING CHAMBER; CELL CULTURE; COLORIMETRY; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROID CELL; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; CELL LINE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM;

CELL LINE; CELL PROLIFERATION; DRUG RESISTANCE; ERYTHROID CELLS; ERYTHROPOIETIN; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TYROSINE;

EID: 84898674100     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355770     Document Type: Article

References (30)

1. Rossert J, Gassmann-Mayer C, Frei D, McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794-800
2. Bamgbola O: Resistance to erythropoietin-stimulating agents: Etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 2012;27:195-205
3. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: European Best Practice Guidelines Working Group Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;S2:ii1-47
4. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, De Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F,Rossert J, McMurray JJ, Pfeffer MA: Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-1155
5. Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, Mehrotra R: Mortality associated with dose response of erythropoiesis- stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 2012;35:198-208
6. Fu P , Jiang X , Arcasoy MO: Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009;379:696-701
7. Yamaji R , Okada T , Moriya M , Naito M , Tsuruo T , Miyatake K , Nakano Y: Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA . Eur J Biochem 1996;239:494-500
8. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R: Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death . Neuroscience 1997;76:105-116
9. Mikolás E, Cseh J, Pap M, Szijártó IA, Balogh A, Laczy B, Bekó V, Fisi V, Molnár GA, Mérei Á, Szeberényi J, Wittmann I: Effects of Erythropoietin on Glucose Metabolism. Horm Metab Res 2012;44: 279-285
10. Hitomi K, Fujita K, Sasaki R, Chiba H, Okuno Y, Ichiba S, Takahashi T, Imura H: Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochem Biophys Res Commun 1988;154:902-909
11. Nakazawa M, Mitjavila MT, Debili N, Casadevall N, Mayeux P, Rouyer-Fessard P, Dubart A, Roméo PH, Beuzard Y, Kishi K et al: KU 812: A pluripotent human cell line with spontaneous erythroid terminal maturation. Blood 1989;73:2003-2013
12. Kitamura T, Tojo A, Kuwaki T, Chiba S, Miyazono K, Urabe A, Takaku F: Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989;73:375-380
13. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-236
14. Watowich SS: The Erythropoietin Receptor: Molecular Structure and Hematopoietic Signaling Pathways. J Investig Med 2011;59:1067-1072
15. Woolf LI, Jakubovic A, Chan-Henry E: The non-enzymic hydroxylation of phenylalanine to tyrosine by 2-Amino-4-hydroxy-6,7-dimethyl-5,6,7,8- Tetrahydropteridine. Biochem J 1971;125:569-574
16. Gurer-Orhan H, Ercal N, Mare S, Pennathur S, Orhan H, Heinecke JW: Misincorporation of free m-Tyrosine into cellular proteins: A potential cytotoxic mechanism for oxidized amino acids. Biochem J 2006;395:277-284
17. Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD: Concomitant tumor resistance: The role of tyrosine isomers in the mechanisms of metastases control. Cancer Res 2012;72:1043-1050
18. Ruggiero RA, Bruzzo J, Chiarella P, di Gianni P, Isturiz MA, Linskens S, Speziale N, Meiss RP, Bustuoabad OD, Pasqualini CD: Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Res 2011;71:7113-7124
19. Molnár GA, Wagner Z, Markó L, Kó Szegi T, Mohás M, Kocsis B, Matus Z, Wagner L, Tamaskó M, Mazák I, Laczy B, Nagy J, Wittmann I: Urinary ortho-Tyrosine excretion in diabetes mellitus and renal failure: Evidence for hydroxyl radical production. Kidney Int 2005;68:2281-2287
20. Mima A: Inflammation and oxidative stress in diabetic nephropathy: New insights on its inhibition as new therapeutic targets. J Diabetes Res 2013;2013:248563
21. Magenta A, Greco S, Gaetano C, Martelli F: Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 2013;14:17319-17346
22. Misra MK, Sarwat M, Bhakuni P, Tuteja R, Tuteja N: Oxidative stress and ischemic myocardial syndromes. Med Sci Monit 2009;15:RA209-RA219
23. Bertin C, Weston LA, Huang T, Jander G, Owens T, Meinwald J, Schroeder FC: Grass roots chemistry: Metatyrosine, an herbicidal nonprotein amino acid. Proc Natl Acad Sci USA 2007;104:16964-16969
24. Rodgers KJ, Wang H, Fu S, Dean RT: Biosynthetic incorporation of oxidized amino acids into proteins and their cellular proteolysis. Free Radic Biol Med 2002;32:766-775
25. Ershler WB, Sheng S, McKelvey J, Artz AS, Denduluri N, Tecson J, Taub DD, Brant LJ, Ferrucci L, Longo DL: Serum erythropoietin and aging: A longitudinal analysis. J Am Geriatr Soc 2005;53:1360-1365
26. Vanasse GJ, Berliner N: Anemia in elderly patients: An emerging problem for the 21st century. Hematology Am Soc Hematol Educ Program 2010;2010:271-275
27. Dai DF, Rabinovitch PS, Ungvari Z: Mitochondria and cardiovascular aging. Circ Res 2012;110:1109-1124
28. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
29. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM: Cardiovascular toxicity of epoetin-Alfa in patients with chronic kidney disease. Am J Nephrol 2013;37:549-558
30. Ausk KJ, Boyko EJ, Ioannou GN: Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care 2010;33:1179-1185